AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28734553 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-inflammatory dietary pattern
Number of subjects: 794
Study 27304196 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar (2.5 mg q.d. for 7 days)
Number of subjects: 36
Study 27304196 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg q.d. for 7 days)
Number of subjects: 36
Study 27304196 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar + Aspirin (for 7 days)
Number of subjects: 36
Study 27304196 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (for 7 days)
Number of subjects: 36
Study 24699310 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex(®) low dose (5.4mg THC)
Number of subjects: 0
Study 24699310 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex(®) high dose (21.6mg THC)
Number of subjects: 0
Study 24699310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23896849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation with supplemental Internet-based homework (10 weeks of weekly group sessions and daily online cognitive exercises)
Number of subjects: 0
Study 23896849 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 0
Study 23896849 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Number of subjects: 0
Study 23896849 — intervention group
Group type: EXPERIMENTAL
Intervention: Online cognitive exercises
Number of subjects: 0
Study 20843504 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclectin (doxylamine succinate 10 mg-pyridoxine hydrochloride 10 mg, delayed-release preparation)
Number of subjects: 256
Study 20843504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 20843504 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclectin
Number of subjects: 256
Study 17507912 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-nicotine cigarettes
Number of subjects: 24
Study 17507912 — intervention group
Group type: EXPERIMENTAL
Intervention: High-nicotine cigarettes
Number of subjects: 24
Study 17507912 — intervention group
Group type: EXPERIMENTAL
Intervention: Both low- and high-nicotine cigarettes
Number of subjects: 24
Study 16914459 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. N-acetylcysteine (NAC)
Number of subjects: 80
Study 16914459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 14597936 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/d
Number of subjects: 917
Study 14597936 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg/d
Number of subjects: 917
Study 11109407 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based intervention
Number of subjects: 3
Study 11109407 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 8737752 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 3 mg
Number of subjects: 86
Study 8737752 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 6 mg
Number of subjects: 86
Study 8737752 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 3 mg and 6 mg
Number of subjects: 86
Study 1331494 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g kg‐1 body mass)
Number of subjects: 4
Study 1331494 — intervention group
Group type: COMPARATOR
Intervention: Control and placebo conditions
Number of subjects: 4
Study 3874640 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 3874640 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 0
Study 3874640 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 0
Study 31559948 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating Pressure Mattress (APM)
Number of subjects: 2029
Study 31559948 — intervention group
Group type: COMPARATOR
Intervention: High-Specification Foam Mattress (HSFM)
Number of subjects: 2029
Study 28489759 — intervention group
Group type: EXPERIMENTAL
Intervention: Shen-Cao granules
Number of subjects: 200
Study 28489759 — intervention group
Group type: COMPARATOR
Intervention: Control (no Shen-Cao granules)
Number of subjects: 200
Study 26042031 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustically controlled auditory training (ACAT)
Number of subjects: 16
Study 26042031 — intervention group
Group type: COMPARATOR
Intervention: Placebo training (Active Control Group)
Number of subjects: 16
Study 26042031 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Passive Control Group)
Number of subjects: 16
Study 23680589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) iron (Iron Sucrose 200 mg, once a week for 5 weeks)
Number of subjects: 18
Study 23680589 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral (p.o.) iron (ferrous sulfate 200 mg TID for 8 weeks)
Number of subjects: 18
Study 23680589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21642644 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (100-200 µg)
Number of subjects: 29
Study 21642644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (5-20 mg)
Number of subjects: 29
Study 19451440 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline EORTC QLQ‐C30 physical functioning (PF) score
Number of subjects: 540
Study 19451440 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in HRQOL dimensions, specifically PF change
Number of subjects: 540
Study 19451440 — intervention group
Group type: COMPARATOR
Intervention: No other HRQOL variable
Number of subjects: 540
Study 16719616 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied tension technique (treatment condition)
Number of subjects: 467
Study 16719616 — intervention group
Group type: COMPARATOR
Intervention: Applied tension technique (placebo condition)
Number of subjects: 467
Study 16719616 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 467
Study 16719616 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 467
Study 15560813 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental anti‐plaque paste (test)
Number of subjects: 22
Study 15560813 — intervention group
Group type: COMPARATOR
Intervention: Experimental paste (minus active or negative control)
Number of subjects: 22
Study 15560813 — intervention group
Group type: COMPARATOR
Intervention: Proprietary anti‐plaque toothpaste product (positive control)
Number of subjects: 22
Study 11736621 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (group exercise 3 times a week for 8 weeks, including calisthenics, stationary bicycling, and walking)
Number of subjects: 10
Study 11736621 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 10
Study 11736621 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 10
Study 9209247 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cotinine treatment (0.25 mg/kg twice a day)
Number of subjects: 12
Study 9209247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9209247 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cotinine-d4 infusion
Number of subjects: 12
Study 9209247 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine derived from nicotine
Number of subjects: 12
Study 8080160 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid solution containing acetate
Number of subjects: 30
Study 8080160 — intervention group
Group type: COMPARATOR
Intervention: Amino acid solution without acetate
Number of subjects: 30
Study 3454320 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 0
Study 3454320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29321067 — intervention group
Group type: EXPERIMENTAL
Intervention: MOH plus Alcohol-Containing essential oil Mouthrinse (ACM)
Number of subjects: 370
Study 29321067 — intervention group
Group type: EXPERIMENTAL
Intervention: MOH plus Alcohol-Free essential oil Mouthrinse (AFM)
Number of subjects: 370
Study 29321067 — intervention group
Group type: COMPARATOR
Intervention: Mechanical Oral Hygiene (MOH) only
Number of subjects: 370
Study 27710817 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured newborn care education programme (one-on-one educational sessions lasting 10-15 minutes each and one postpartum follow-up telephone support within two weeks after discharge)
Number of subjects: 143
Study 27710817 — intervention group
Group type: COMPARATOR
Intervention: Regular general newborn care education (control group)
Number of subjects: 143
Study 24188861 — intervention group
Group type: EXPERIMENTAL
Intervention: Helping Alliance Questionnaire I (measured twice, middle and late during treatment)
Number of subjects: 0
Study 24188861 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton Depression Rating Scale
Number of subjects: 0
Study 22705035 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy (STPP)
Number of subjects: 198
Study 22705035 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-focused therapy (SFT)
Number of subjects: 198
Study 20530276 — intervention group
Group type: EXPERIMENTAL
Intervention: ixabepilone (40 mg/m² intravenously on day 1) plus capecitabine (2,000 mg/m² orally on days 1 through 14)
Number of subjects: 1221
Study 20530276 — intervention group
Group type: EXPERIMENTAL
Intervention: ixabepilone plus capecitabine
Number of subjects: 1221
Study 20530276 — intervention group
Group type: COMPARATOR
Intervention: capecitabine alone (2,500 mg/m² on the same schedule)
Number of subjects: 1221
Study 18405814 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbst appliance (combined with fixed appliances)
Number of subjects: 48
Study 18405814 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear (combined with fixed appliances)
Number of subjects: 48
Study 16633890 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (Dosage Form A, 3 mg)
Number of subjects: 20
Study 16633890 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (Dosage Form A, 9 mg)
Number of subjects: 20
Study 16633890 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (Dosage Form B, 9 mg)
Number of subjects: 20
Study 16633890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12728189 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory guidance provided by pediatricians regarding contraception
Number of subjects: 0
Study 12728189 — intervention group
Group type: EXPERIMENTAL
Intervention: Least effective contraceptive methods
Number of subjects: 0
Study 10663279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine alone (150 mg preoperatively per os and 50 mg intravenously postoperatively)
Number of subjects: 64
Study 10663279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine combined with dobutamine (150 mg preoperatively per os and 50 mg intravenously postoperatively + dobutamine 4 micro g. kg(‐1). min(‐1) for 3 h postoperatively)
Number of subjects: 64
Study 10663279 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine alone (4 micro g. kg(‐1). min(‐1) for 3 h postoperatively)
Number of subjects: 64
Study 10663279 — intervention group
Group type: COMPARATOR
Intervention: Neither ranitidine nor dobutamine (control group)
Number of subjects: 64
Study 8797464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (1 g/kg body weight/day for 2 days, total dose 2.0 g/kg body weight)
Number of subjects: 9
Study 8797464 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.3% albumin equivalent volume)
Number of subjects: 9
Study 1545091 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak expiratory flow rate measurements
Number of subjects: 10
Study 1545091 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 PM FEV1 values
Number of subjects: 10
Study 1545091 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 AM FEV1 values
Number of subjects: 10
Study 1545091 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 PM PC20 (provocative concentration of methacholine)
Number of subjects: 10
Study 1545091 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 AM PC20 (provocative concentration of methacholine)
Number of subjects: 10
Study 1545091 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial responsiveness
Number of subjects: 10
Study 7106950 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (4% by weight)
Number of subjects: 12
Study 7106950 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation (0.5% by weight)
Number of subjects: 12
Study 7106950 — intervention group
Group type: COMPARATOR
Intervention: Low calcium diet (0.25% by weight)
Number of subjects: 12
Study 30905652 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term high-dose albumin (1.5 g/kg every week)
Number of subjects: 96
Study 30905652 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term low-dose albumin (1 g/kg body weight every 2 weeks)
Number of subjects: 96
Study 30905652 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term albumin plus antibiotics (1.5 g/kg on day 1 and 1 g/kg on day 3)
Number of subjects: 96
Study 30905652 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone (control group)
Number of subjects: 96
Study 30572835 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task exercise program
Number of subjects: 300
Study 30572835 — intervention group
Group type: COMPARATOR
Intervention: Recruitment strategies (various approaches including information packs, presentations, testing)
Number of subjects: 300
Study 26676176 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 53
Study 25014045 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm weight support device
Number of subjects: 28
Study 25014045 — intervention group
Group type: COMPARATOR
Intervention: Traditional physiotherapy
Number of subjects: 28
Study 18267994 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary patient education intervention
Number of subjects: 90
Study 18267994 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 90
Study 15209626 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (IFN-alpha-2b + hepatitis B vaccine)
Number of subjects: 50
Study 15209626 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha-2b monotherapy
Number of subjects: 50
Study 11324727 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily 3 MU of IFN beta (group A)
Number of subjects: 20
Study 11324727 — intervention group
Group type: COMPARATOR
Intervention: Once-daily 6 MU of IFN-beta (group B)
Number of subjects: 20
Study 11324727 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects of IFN
Number of subjects: 20
Study 9040326 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine clinic review
Number of subjects: 210
Study 9040326 — intervention group
Group type: COMPARATOR
Intervention: Routine physical examination
Number of subjects: 210
Study 7943596 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 0
Study 7943596 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 0
Study 3285170 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1 mg. kg‐1
Number of subjects: 20
Study 3285170 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 11427138 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use during more than 25% of sex acts
Number of subjects: 528
Study 11427138 — intervention group
Group type: COMPARATOR
Intervention: Initial 150-day interval
Number of subjects: 528
Study 11427138 — intervention group
Group type: COMPARATOR
Intervention: Final 150-day interval
Number of subjects: 528
Study 30690691 — intervention group
Group type: EXPERIMENTAL
Intervention: VEL-091604 cream applied 2 times daily for 2 weeks
Number of subjects: 10
Study 30690691 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone acetate
Number of subjects: 10
Study 30690691 — intervention group
Group type: EXPERIMENTAL
Intervention: VEL-091604 cream in atopic dermatitis subjects
Number of subjects: 10
Study 30690691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28592196 — intervention group
Group type: EXPERIMENTAL
Intervention: Forever Free (FF) relapse prevention booklets
Number of subjects: 225
Study 28592196 — intervention group
Group type: COMPARATOR
Intervention: Control booklet (Surgeon General's report, SG)
Number of subjects: 225
Study 26462570 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term meditation (MG) with positive suggestions
Number of subjects: 59
Study 26462570 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term meditation (MG) with negative suggestions
Number of subjects: 59
Study 26462570 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation control group (ECG) with positive suggestions
Number of subjects: 59
Study 26462570 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation control group (ECG) with negative suggestions
Number of subjects: 59
Study 26462570 — intervention group
Group type: COMPARATOR
Intervention: Passive control group (CG)
Number of subjects: 59
Study 25416602 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate (OCA)
Number of subjects: 42
Study 25416602 — intervention group
Group type: COMPARATOR
Intervention: Surgical repair
Number of subjects: 42
Study 22592214 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.05mg/kg)
Number of subjects: 100
Study 22592214 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (0.9% NaCl)
Number of subjects: 100
Study 19878508 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg weekly for 4 weeks
Number of subjects: 51
Study 19878508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 17367313 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg alum-formulated rhGAD65
Number of subjects: 47
Study 17367313 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg alum-formulated rhGAD65
Number of subjects: 47
Study 17367313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 15922068 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% coherence level
Number of subjects: 0
Study 15922068 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% coherence level
Number of subjects: 0
Study 15922068 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% coherence level
Number of subjects: 0
Study 15922068 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% coherence level
Number of subjects: 0
Study 15922068 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-alone condition
Number of subjects: 0
Study 11828040 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial hyperresponsiveness (BHR) tests
Number of subjects: 1633
Study 11828040 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom history
Number of subjects: 1633
Study 11828040 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model with four symptoms
Number of subjects: 1633
Study 11828040 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model with symptoms, free running test, and methacholine inhalation challenge results
Number of subjects: 1633
Study 10036612 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 1.0 mg
Number of subjects: 21
Study 10036612 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2.0 mg
Number of subjects: 21
Study 10036612 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg
Number of subjects: 21
Study 10036612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8751336 — intervention group
Group type: EXPERIMENTAL
Intervention: Visaline
Number of subjects: 20
Study 8751336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1975113 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg/kg
Number of subjects: 99
Study 1975113 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 99
Study 1975113 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg/kg
Number of subjects: 99
Study 6944708 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine 0.5 mg i.m.
Number of subjects: 8
Study 6944708 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 0.5 mg i.m.
Number of subjects: 8
Study 31713262 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic sensory intervention (SI) including hearing and vision assessment and provision of glasses and/or hearing aids
Number of subjects: 19
Study 31713262 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended sensory intervention (SI) with additional weekly visits from a sensory support therapist (SST)
Number of subjects: 19
Study 31713262 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic sensory intervention (SI)
Number of subjects: 19
Study 30601215 — intervention group
Group type: EXPERIMENTAL
Intervention: Confident, high-power body language
Number of subjects: 200
Study 30601215 — intervention group
Group type: COMPARATOR
Intervention: Unconfident, low-power body language
Number of subjects: 200
Study 28412009 — intervention group
Group type: EXPERIMENTAL
Intervention: Music during ESWL
Number of subjects: 95
Study 28412009 — intervention group
Group type: COMPARATOR
Intervention: No music during ESWL
Number of subjects: 95
Study 25820213 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV+ES
Number of subjects: 13
Study 25820213 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV30/ES30
Number of subjects: 13
Study 25820213 — intervention group
Group type: COMPARATOR
Intervention: WBV
Number of subjects: 13
Study 25820213 — intervention group
Group type: COMPARATOR
Intervention: ES
Number of subjects: 13
Study 24375332 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Acupuncture (RA)
Number of subjects: 47
Study 24375332 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 47
Study 22571890 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful Waiting Death (WWD)
Number of subjects: 208
Study 22571890 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative Death (PD)
Number of subjects: 208
Study 22571890 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful Operation (SO)
Number of subjects: 208